Director dealings
05 November 2026
AIM: EDX
("EDX Medical" or the "Company")
Director dealings
CAMBRIDGE, UK: EDX Medical Group plc, which develops and supplies innovative digital diagnostic products and services to improve the early detection and treatment of major diseases, announces that it was informed on 04 November 2026 that Dr Michael Hudson, Chief Executive Officer of the Company, purchased a total of 75,000 ordinary shares in the Company via open market trading on 04 November 2026 at an average price of 6.83 pence per share.
The Company was also informed on 04 November 2026 that Sebastian Hudson, a person closely associated with Dr Michael Hudson, purchased a total of 25,000 shares via open market trading on 04 November 2026 at an average price per share of 6.75 pence per share. Sebastian Hudson now holds 75,000 ordinary shares in the Company.
Taken together, Dr Hudson controls 20,750,000 ordinary shares, representing 4.81% of the Company's issued share capital.
This announcement is made in accordance with Article 19(1) of the EU Market Abuse Regulation as incorporated into UK law through the European Union (Withdrawal) Act 2018. The directors of the Company accept responsibility for the contents of this announcement.
1
Details of PDMR / person closely associated with them ("PCA")
(a)
Name
Dr Michael Hudson
2
Reason for the notification
(a)
Position/status
PDMR/CEO
(b)
Initial notification/amendment
Initial notification
3
Details of the Issuer
(a)
Name
EDX Medical Group plc
(b)
Legal Entity Identifier code
213800BZVJZTMCZ6DJ63
4
Details of the transaction(s)
(a)
Description of the financial instrument
Ordinary shares of £0.01 each
(b)
Identification Code
ISIN: GB00BNDMJS47
(c)
Nature of the transaction
Purchase of shares on market
(d)
Currency
GBP
(e)
Price(s) and volume(s)
Price(s)
Volume(s)
6.5p
35,000
6.99p
5,000
7.0p
35,000
[(f)
Aggregated information
- Aggregated volume
- Price
75,000 shares
£0.0683
(g)
Date of the transaction
04-11-2026
(h)
Place of the transaction
XLON:AIMX
1
Details of PDMR / person closely associated with them ("PCA")
(a)
Name
Sebastian Hudson
2
Reason for the notification
(a)
Position/status
Person Closely Associated with Dr Michael Hudson
(b)
Initial notification/amendment
Initial notification
3
Details of the Issuer
(a)
Name
EDX Medical Group plc
(b)
Legal Entity Identifier code
213800BZVJZTMCZ6DJ63
4
Details of the transaction(s)
(a)
Description of the financial instrument
Ordinary shares of £0.01 each
(b)
Identification Code
ISIN:GB00BNDMJS47
(c)
Nature of the transaction
Purchase of shares on market
(d)
Currency
GBP
(e)
Price(s) and volume(s)
Price(s)
Volume(s)
6.5p
10,000
7p
15,000
[(f)
Aggregated information
- Aggregated volume
- Price
25,000 shares
£0.0675
(g)
Date of the transaction
04-11-2026
(h)
Place of the transaction
XLON:AIMX
For enquiries, please contact:
EDX Medical Group plc
Dr Mike Hudson (Chief Executive Officer)
+44 (0)7812 345 301
Canaccord Genuity Limited (Nominated Adviser and Broker)
Stuart Andrews
+44 (0) 20 7523 8318
Media House International
Ramsay Smith
Gary McQueen
+44 (0)7788 414856
+ 44 (0)7834 694609
IFC Advisory (Investor Relations)
Graham Herring
Tim Metcalfe
+44 (0) 203 934 6630
About EDX Medical Group plc
EDX Medical Group plc is listed on the AIM market (TIDM: EDX).
EDX Medical was founded by Professor Sir Christopher Evans, OBE, a medical and life sciences entrepreneur with more than 30 years of experience, together with CEO, Dr Mike Hudson.
By translating clinical insights into pragmatic solutions combining advanced biological and digital technologies, EDX Medical seeks to cost effectively improve the detection and characterisation of disease to personalise treatment in a timely fashion. Early disease detection and biologically based personal treatment optimisation is considered to be the most impactful way of improving patient outcomes, reducing deaths and lowering the cost of healthcare globally.
EDX Medical Group provides doctors, hospitals and insurers/payers with access to a portfolio of the best clinical diagnostics products and services. The Company operates its own facilities in Cambridge, UK, and has strategic product and technology partnerships with organisations such as Thermo Fisher EMEA Ltd, a world leader in supplying life sciences solutions and services.
This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.
RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.ENDDSHFLFVVLTLEIIR
